TNFRSF8 and T-cell non-Hodgkin lymphoma: This work showcased the efficacy of 161Tb radioimmunotherapy for the treatment of CD30-positive T-cell lymphomas and represents the first study evaluating this therapeutic radionuclide for the treatment of hematologic malignancies.